3.87.33.97
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Industry News

RegenxBio announces start of phase 3 trial of gene therapy for wet AMD

A late-stage clinical trial to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (wet AMD) is underway, according to RegenxBio Inc. RGX-314 is being investigated as a potential one-time gene therapy for the treatment of wet AMD. ASCENT, which is being...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-